Biotie regains rights to develop PDE10 inhibitors for CNS disorders
Advertisement
Biotie announced that it will regain rights to compounds relating to PDE10 inhibition for the treatment of CNS disorders, including schizophrenia. The compounds were the subject of a four-year collaboration with Wyeth (which was acquired by Pfizer in 2009) which started in 2006 and which yielded several promising PDE10 inhibitors that have demonstrated activity in pre-clinical models of schizophrenia.
Timo Veromaa, Chief Executive Officer of Biotie commented, "We are excited about PDE10 as a novel target for the treatment of schizophrenia and other disorders of the central nervous system. We have had a succesful research collaboration with Wyeth, and then Pfizer, and together we have generated supportive data for this class. We are now in a position to pursue novel clinical candidates going forward."